Integrated transcriptomics and network pharmacology analysis demonstrated that the therapeutic effect of DQJD on the CCH model might be mediated by the activation of the RXR‐γ/PPAR‐γ/VEGF‐α signalling pathway. The gene discussed is RXRG; the disease is columnar cell hyperplasia of the breast.